On 6 November 2016, in conjunction with the first year anniversary of vortioxetine (Brintellix®, Lundbeck) in Malaysia, two distinguished speakers, Professor Gin S Malhi and Dr Pranab Kalita shared updates on depression and the use of vortioxetine in order to help patients with major depressive disorders (MDD) to return to their premorbid functional states. The session was followed by three case presentations.
This newsletter features an interview with Prof Dr. Nor Zuraida Zainal, president of the Malaysian Psychiatric Association (MPA) and Dr. Abdul Rasyid Sulaiman, programme director of the MPA Depression Awareness Day 2016. It also includes highlights of recent discoveries in depression research.
This article presents the excerpts from the Inaugural Meeting of the Dementia Advisory Board Malaysia held on 23 January 2016 in Kuala Lumpur, highlighting the clinical evidence of Ginkgo biloba extract EGb761® in dementia, treatment recommendations from international guidelines and consensus reached during the meeting on the role of EGb761® in managing dementia.
During the launch of Brintellix® (vortioxetine) in Malaysia, Professor Dr Nor Zuraida Zainal, Associate Professor Dr Gregory W Mattingly and Associate Professor Dr Ng Chong Guan provided an overview on depression, as well as expounded the role of vortioxetine in treating depression or major depressive episode.
Ginkgo biloba has been shown to improve cognitive as well as neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) and mixed dementia. During a Schwabe-sponsored symposium last 20 October 2014 held at the University of Malaya in Malaysia, Professor Serge Gauthier of the McGill Centre for Studies in Aging in Quebec, Canada, and Dr Robert Hoerr of the Dr Willmar Schwabe GmbH & Co. KG in Germany, discussed studies that support the safety and efficacy of Ginkgo biloba extract (EGb 761®) in patients with AD and dementia.
This is the case of a 32-year-old male who called the Early Assessment Service for Young People with Psychosis (EASY Program) hotline due to insomnia in February 2014. The patient had no history of substance abuse, did not smoke, and did not drink alcohol. Family history was negative for mental illness. At the time of the call, he worked as a hairstylist, had one sibling, and lived in a public housing estate. He had a poor employment history, having worked at various jobs with no job lasting more than 2 years. Medical history was unremarkable.
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.